Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon May 06, 2021 1:02pm
98 Views
Post# 33141584

RE:RE:RE:RE:RE:RE:No institutions, IP, Nasdaq, timeline meet

RE:RE:RE:RE:RE:RE:No institutions, IP, Nasdaq, timeline meet
JPkatz wrote:
Don't put words in Danny's mouth... he says 'conclude a series of transformational partnerships over the next 12-18 months', Not ENGAGE as you say. Anyway at what point do we hold Dan accountable for his performance?? The only thing we can count on with him is he never fails to disappoint... From the citagenix deal, excessive dilution and numerous empty promises I think he has done a horrible job and think it's time for a new CEO to take this company to the next level! Just my opinion


JP - just reread that article and think about what's happened since.
Think about the partnerships that did happen (e.g. South Korea, Academic Partnership) - they were transformational as they started the ball rolling and we've been going to market has higher valuations since (but not as high as some would like).  We got to the TSX and now we're even in China.  

It wasn't about Big Pharma in that article, it was partnerships ... though you are trying to make that quick connection to BP.

Regardless - believe what you want.

If you were here since that article was written, you would be well in tune with what we're expecting on a month by month basis.   We've had good discussions trying to keep everyone in the know.  We even have people making calls to the ATE team to get us the latest.

One big party !

-------------------------



<< Previous
Bullboard Posts
Next >>